APRE Stock Price, Aprea Therapeutics Inc Quote, Chart

Market Summary

USD5.27-0.32

Delayed

-5.72%

APRE Stock Price

View Fullscreen

APRE RSI Chart

APRE Valuation

Market Cap

28.6M

Price/Earnings (Trailing)

-2.25

Price/Sales (Trailing)

49.07

Price/Free Cashflow

-2.16

APRE Price/Sales (Trailing)

APRE Profitability

Return on Equity

-43.97%

Return on Assets

-38.3%

Free Cashflow Yield

-46.22%

APRE Fundamentals

APRE Revenue

Revenue (TTM)

583.2K

APRE Earnings

Earnings (TTM)

-12.7M

Earnings Growth (Yr)

35.84%

Earnings Growth (Qtr)

18.39%

Breaking Down APRE Revenue

Last 7 days

-5.7%

Last 30 days

-8.0%

Last 90 days

-9.6%

Trailing 12 Months

41.0%

How does APRE drawdown profile look like?

APRE Financial Health

Current Ratio

11.15

APRE Investor Care

Shares Dilution (1Y)

45.52%

Diluted EPS (TTM)

-3.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	583.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aprea Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	mirza nadeem q.	acquired	-	-	6,730	chief medical officer
Mar 28, 2024	hamill john p.	acquired	-	-	3,365	srvp/cfo/prin fin & acct ofcr
Mar 28, 2024	gilad oren	acquired	-	-	6,725	president, ceo
Mar 13, 2024	henneman john b iii	bought	50,009	7.29	6,860	-
Mar 13, 2024	seizinger bernd r.	bought	50,009	7.29	6,860	-
Mar 13, 2024	gilad oren	bought	14,580	7.29	2,000	president, ceo
Mar 13, 2024	hamill john p.	bought	7,362	7.29	1,010	srvp/cfo/prin fin & acct ofcr
Aug 23, 2023	seizinger bernd r.	acquired	-	-	500	-
Aug 23, 2023	pamukcu rifat	acquired	-	-	500	-
Aug 23, 2023	grissinger michael	acquired	-	-	500	-

Which funds bought or sold APRE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	added	55.76	98,487	179,412	-%
May 15, 2024	Royal Bank of Canada	reduced	-94.16	-190,000	17,000	-%
May 15, 2024	DAFNA Capital Management LLC	new	-	917,694	917,694	0.21%
May 15, 2024	Nantahala Capital Management, LLC	new	-	1,376,530	1,376,530	0.08%
May 15, 2024	Sio Capital Management, LLC	reduced	-1.21	534,474	1,850,470	0.55%
May 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	new	-	1,806,300	1,806,300	0.25%
May 15, 2024	Tower Research Capital LLC (TRC)	added	105	4,957	7,533	-%
May 15, 2024	Walleye Capital LLC	sold off	-100	-376,000	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-51.83	-4,803	10,477	-%
May 14, 2024	AIGH Capital Management LLC	added	54.39	1,863,110	3,504,820	1.05%

Are Funds Buying or Selling APRE?

Are funds buying APRE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APRE

No. of Funds

Unveiling Aprea Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	sio capital management, llc	7.49%	280,000	SC 13G
Feb 07, 2024	hirschman orin	9.4%	349,300	SC 13G/A
Mar 03, 2023	hirschman orin	9.2%	345,000	SC 13G
Nov 15, 2022	healthcap vii, l.p.	4.5%	2,366,104	SC 13D/A
Jun 30, 2022	healthcap vii, l.p.	10.1%	2,366,104	SC 13D/A
Feb 14, 2022	redmile group, llc	0%	0	SC 13G/A
Feb 11, 2022	versant ventures v, llc	0.0%	0	SC 13G/A
Oct 15, 2021	healthcap vii, l.p.	11.2%	2,366,104	SC 13D/A
Oct 12, 2021	morgan stanley	0.9%	184,964	SC 13G/A
Mar 24, 2021	morgan stanley	5.1%	1,072,411	SC 13G

Recent SEC filings of Aprea Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 02, 2024	3	Insider Trading
May 02, 2024	4	Insider Trading
Apr 30, 2024	424B3	Prospectus Filed
Apr 29, 2024	EFFECT	EFFECT
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 10, 2024	8-K	Current Report

Peers (Alternatives to Aprea Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Aprea Therapeutics Inc News

Latest updates

Aprea Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2
Revenue	8.7%	381	350	319	250
Operating Expenses	-4.3%	3,530	3,689	3,842	3,901
S&GA Expenses	-100.0%	-	1,643	1,720	1,699
Net Income	18.4%	-2,810	-3,443	-3,204	-3,259
Net Income Margin	11.0%	-21.80*	-24.50*	-	-
Free Cashflow	-5.3%	-3,943	-3,746	-2,258	-3,233

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	46.6%	33.00	23.00	26.00	29.00	32.00	30.00	34.00	41.00	50.00	57.00	62.00	72.00	80.00	93.00	103	115	125	134	57.00	66.00
Current Assets	46.8%	33.00	23.00	26.00	29.00	32.00	30.00	33.00	40.00	50.00	57.00	62.00	71.00	80.00	92.00	102	114	125	133	57.00	66.00
Cash Equivalents	50.0%	32.00	22.00	25.00	28.00	31.00	29.00	33.00	39.00	48.00	53.00	61.00	70.00	78.00	89.00	101	113	123	130	52.00	66.00
Net PPE	2.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-	-	-	-	4.00	4.00	3.00	4.00	8.00	7.00	7.00	9.00	11.00	11.00	15.00	14.00	15.00	12.00	9.00	10.00	5.00
Current Liabilities	-32.4%	3.00	4.00	4.00	4.00	4.00	3.00	4.00	8.00	7.00	7.00	9.00	11.00	11.00	15.00	14.00	15.00	12.00	9.00	10.00	5.00
Shareholder's Equity	70.6%	29.00	17.00	20.00	23.00	26.00	26.00	27.00	-	44.00	50.00	53.00	61.00	69.00	77.00	89.00	100	113	124	-	-
Retained Earnings	-0.9%	-310	-308	-304	-301	-298	-293	-291	-287	-189	-181	-173	-163	-153	-144	-128	-116	-99.93	-90.53	-77.46	-62.47
Additional Paid-In Capital	4.4%	350	336	336	335	335	330	328	262	243	241	237	235	233	231	230	229	227	226	20.00	20.00
Shares Outstanding	45.3%	5.00	4.00	4.00	4.00	4.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-
Float	-	-	-	-	10.00	-	-	-	14.00	-	-	-	70.00	-	-	-	264	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-5.2%	-3,935	-3,739	-2,241	-3,216	-2,979	-4,020	-6,592	-8,902	-5,495	-10,178	-8,233	-7,751	-11,522	-13,199	-11,423	-9,638	-7,541	-14,742	-2,793	-4,975	-4,197
Cashflow From Investing	-11.6%	-7.98	-7.15	-	-	-	-	-	-	-	-	-	-	-	-16.29	725*	2.00	-12.16	-14.47	-10.25	-	-
Cashflow From Financing	-	14,710	-	-	-	5,140	99.00	-	-	-	1,660	-	-	-	-	-	121	30.00	91,198	-3,619	-435	5,433

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APRE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 380,569
Operating expenses:
Research and development	1,600,373	$ 1,256,542
General and administrative	1,929,866	3,365,961
Total operating expenses	3,530,239	4,622,503
Loss from operations	(3,149,670)	(4,622,503)
Other income (expense):
Interest income, net	283,403	256,410
Foreign currency gain (loss)	56,176	(13,797)
Total other income	339,579	242,613
Net loss	(2,810,091)	(4,379,890)
Other comprehensive (loss) gain:
Foreign currency translation	(15,083)	61,956
Total comprehensive loss	$ (2,825,174)	$ (4,317,934)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.67)	$ (1.34)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.67)	$ (1.34)
Weighted-average common shares outstanding, basic (in shares)	4,198,326	3,260,484
Weighted-average common shares outstanding, diluted (in shares)	4,198,326	3,260,484

APRE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,369,973	$ 21,606,820
Prepaid expenses and other current assets	698,864	914,275
Total current assets	33,068,837	22,521,095
Property and equipment, net	90,183	88,362
Restricted cash	40,986	40,717
Total assets	33,200,006	22,650,174
Current liabilities:
Accounts payable	1,318,385	1,670,369
Accrued expenses	1,498,286	2,186,262
Deferred grant revenue	148,405	528,974
Total current liabilities	2,965,076	4,385,605
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.001 par value, 400,000,000 shares authorized, 5,430,215 and 3,736,673 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5,430	3,736
Additional paid-in capital	350,438,045	335,644,204
Accumulated other comprehensive loss	(10,626,356)	(10,611,273)
Accumulated deficit	(310,893,252)	(308,083,161)
Total stockholders' equity	28,923,867	16,953,506
Total liabilities and stockholders' equity	33,200,006	22,650,174
Series A Convertible Preferred Stock
Convertible preferred stock:
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at March 31, 2024 and December 31, 2023	$ 1,311,063	$ 1,311,063

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

CEO	Dr. Oren Gilad Ph.D.
WEBSITE	aprea.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Aprea Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aprea Therapeutics Inc? What does APRE stand for in stocks?

APRE is the stock ticker symbol of Aprea Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aprea Therapeutics Inc (APRE)?

As of Fri May 17 2024, market cap of Aprea Therapeutics Inc is 28.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers. The fair value of Aprea Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aprea Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APRE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aprea Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APRE is over valued or under valued. Whether Aprea Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aprea Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APRE.

What is Aprea Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, APRE's PE ratio (Price to Earnings) is -2.25 and Price to Sales (PS) ratio is 49.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APRE PE ratio will change depending on the future growth rate expectations of investors.